Insulin Degludec + Octreotide Interaction
Majorinteraction on record
Description
Somatostatin analog may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec
Somatostatin analog may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec